205 related articles for article (PubMed ID: 27771154)
21. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
Marfella R; D'Amico M; Esposito K; Baldi A; Di Filippo C; Siniscalchi M; Sasso FC; Portoghese M; Cirillo F; Cacciapuoti F; Carbonara O; Crescenzi B; Baldi F; Ceriello A; Nicoletti GF; D'Andrea F; Verza M; Coppola L; Rossi F; Giugliano D
Diabetes; 2006 Mar; 55(3):622-32. PubMed ID: 16505224
[TBL] [Abstract][Full Text] [Related]
22. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
23. Alternative splicing variant of the scaffold protein APPL1 suppresses hepatic adiponectin signaling and function.
Galan-Davila AK; Ryu J; Dong K; Xiao Y; Dai Z; Zhang D; Li Z; Dick AM; Liu KD; Kamat A; Lu M; Dong Q; Liu F; Dong LQ
J Biol Chem; 2018 Apr; 293(16):6064-6074. PubMed ID: 29483192
[TBL] [Abstract][Full Text] [Related]
24. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
[TBL] [Abstract][Full Text] [Related]
25. Incretins: what is known, new and controversial in 2013?
Burcelin R; Thorens B;
Diabetes Metab; 2013 Apr; 39(2):89-93. PubMed ID: 23523140
[TBL] [Abstract][Full Text] [Related]
26. Blood pressure-lowering effects of incretin-based diabetes therapies.
Lovshin JA; Zinman B
Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
[TBL] [Abstract][Full Text] [Related]
27. [Incretin modulators, a new perspective in diabetes mellitus treatment].
Lupaşcu FG; Geangalău IM; Pânzariu A; Profire L
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):630-4. PubMed ID: 23077965
[TBL] [Abstract][Full Text] [Related]
28. Comment on Balestrieri et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes 2015;64:1395-1406.
Yu WL; Sun Y
Diabetes; 2015 May; 64(5):e5. PubMed ID: 25908880
[No Abstract] [Full Text] [Related]
29. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
Wick A; Newlin K
J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
[TBL] [Abstract][Full Text] [Related]
30. Perivascular adipose adiponectin correlates with symptom status of patients undergoing carotid endarterectomy.
Sharma G; Tao M; Ding K; Yu D; King W; Deyneko G; Wang X; Longchamp A; Schoen FJ; Ozaki CK; Semel ME
Stroke; 2015 Jun; 46(6):1696-9. PubMed ID: 25967575
[TBL] [Abstract][Full Text] [Related]
31. Response to comment on Balestrieri et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes 2015;64:1395-1406.
Balestrieri ML; Rizzo MR; Barbieri M; Paolisso P; D'Onofrio N; Giovane A; Servillo L; Paolisso G; Marfella R
Diabetes; 2015 May; 64(5):e6. PubMed ID: 25908881
[No Abstract] [Full Text] [Related]
32. Cardiovascular actions of incretin-based therapies.
Ussher JR; Drucker DJ
Circ Res; 2014 May; 114(11):1788-803. PubMed ID: 24855202
[TBL] [Abstract][Full Text] [Related]
33. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
Matuszek B; Lenart-Lipińska M; Nowakowski A
Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
[TBL] [Abstract][Full Text] [Related]
34. Antidiabetic treatment restores adiponectin serum levels and APPL1 expression, but does not improve adiponectin-induced vasodilation and endothelial dysfunction in Zucker diabetic fatty rats.
Schmid PM; Resch M; Schach C; Birner C; Riegger GA; Luchner A; Endemann DH
Cardiovasc Diabetol; 2013 Mar; 12():46. PubMed ID: 23497197
[TBL] [Abstract][Full Text] [Related]
35. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment.
Marfella R; Sardu C; Calabrò P; Siniscalchi M; Minicucci F; Signoriello G; Balestrieri ML; Mauro C; Rizzo MR; Paolisso G; Barbieri M
Diabetes Obes Metab; 2018 Mar; 20(3):723-729. PubMed ID: 28950045
[TBL] [Abstract][Full Text] [Related]
36. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lu Z; Zhang X; Li Y; Jin J; Huang Y
J Endocrinol; 2013 Jan; 216(1):61-71. PubMed ID: 23060524
[TBL] [Abstract][Full Text] [Related]
37. Differentiating incretin-based therapies for population-based health care.
Calabrese D
Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
[TBL] [Abstract][Full Text] [Related]
38. Impact of glucagon-like peptide-1 on endothelial function.
Sjöholm A
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
[TBL] [Abstract][Full Text] [Related]
39. A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice.
Kohashi K; Hiromura M; Mori Y; Terasaki M; Watanabe T; Kushima H; Shinmura K; Tomoyasu M; Nagashima M; Hirano T
J Atheroscler Thromb; 2016; 23(4):441-54. PubMed ID: 26549734
[TBL] [Abstract][Full Text] [Related]
40. CEACAM1 Inhibited IκB-α/NF-κB Signal Pathway Via Targeting MMP-9/TIMP-1 Axis in Diabetic Atherosclerosis.
Yu J; Sun G; Chen Y; Li L; Wang H; Tu D; Li L; Meng Z; Wang Y
J Cardiovasc Pharmacol; 2020 Sep; 76(3):329-336. PubMed ID: 32569018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
